Ribonucleases in tumor growth

Experimental Oncology

Volumn 31, Issue 3, 2009, Pages 127-133

  Shlyakhovenko, V A ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Cancer treatment; Enzymes; Epigenetic regulation; Ribonuclease; RNA

Indexed keywords

RIBONUCLEASE; RIBONUCLEASE INHIBITOR;

CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVITY; ENZYME SPECIFICITY; EPIGENETICS; NONHUMAN; PANCREAS CANCER; REVIEW; TUMOR GROWTH;

ANIMALS; HUMANS; NEOPLASMS; RIBONUCLEASES;

EID: 72449189197     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense - mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Cem 2002; 277: 49374-49382
2. Segerstolpe A, Lundkvist P, Osheim YN, et al. Mrd1p binds to pre-rRNA early during transcription independent of U3 snoRNA and is required for compaction of the prerRNA into small subunit processomes. Nucl Acids Res 2008; 36: 4364-4380
3. Phylactou LA. Ribozyme and peptide-nucleic acid-based gene therapy. Adv Drug Deliv Rev 2000; 44: 97-108. (Pubitemid 30799161)
4. Powers C, Aigner A, Stoica GE, et al. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002; 277: 14153-14158 (Pubitemid 34968027)
5. Bagheri S, Kashani-Sabet M. Ribozymes in the age of molecular therapeutics. Curr Mol Med 2004; 4: 489-506.
6. Shapot VS. Nucleases. Moscow: Medicine, 1968; 212 p (In Russian).
7. Peclet C, de Lamirande G, Daoust R. Sensitivity to RNase treatment of ribosomes and rRNA from normal rat liver and Novikoff hepatoma. Br J Cancer 1982; 45: 140-143 (Pubitemid 12207762)
8. Daoust R. Histochemical comparison of focal losses of RNase and ATPase activities in preneoplastic rat livers. J Histochem Cytochem 1979; 27: 653-669 (Pubitemid 9137762)
9. Reddi KK, Holland JF. Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci USA 1976; 73: 2308-2310
10. Nakane H, Yoshida M, Murakami T. Assesment of the clinical usefulness of serum ribonuclease assays: an indicator for the detection of pancreatic cancer. Gastroenterol Jpn 1979; 14: 55-62. (Pubitemid 9167601)
11. Doran G, Allen-Mersh TG, Reynolds KW. Ribonuclease as a tumor marker for pancreatic carcinoma. J Clin Pathol 1980; 33: 1212-1213 (Pubitemid 11160656)
12. Naskalski JW, Celinski A. Determination of actual activities of acid and alkaline ribonuclease in human serum and urine. Mater med Pol 1991; 23: 107-110
13. Suzuki M, Saxena SK, Boix E, et al. Engineering receptor- mediated cytotoxicity into human ribonucleases by steric blocade of inhibitor interaction. Nat Biotechnol 1999; 17: 227-228
14. Dricy A , Sergiy-Bodan C, Brismar K, et al. A synthetic peptide derived from the human eosinophil-derived neurotoxin induces apoptosis in Kaposi's sarcoma cells. Anticancer Res 2004; 24: 1427-1432 (Pubitemid 38954659)
15. Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42: 1805-1812 (Pubitemid 36258654)
16. Xiang Y, Wang Z, Murakami J, et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2'-5' oligoadenylates. Cancer Res 2003; 63: 6795-6801 (Pubitemid 37322961)
17. Shea PR, Ishwad CS, Bunker CH, et al. RNASEL and RNASEL - inhibitor variation and prostate cancer risk in Afro-Carribeans. Prostate 2008; 68: 354-359
18. Larson BT, Magi-Galluzzi C, Casey G, et al. Pathological aggressiveness of prostatic carcinomas related to RNase LR4 62Q. J Urol 2008; 179: 1344-1348
19. Vihinen P, Kallioinen M, Vuoristo MS, et al. Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin Exp Metastasis 2007; 24: 567-574 (Pubitemid 47524814)
20. Youle RY, Newton D, Wu YN, et al. Cytotoxic ribonucleases and chimeras in cancer therapy. Crit Rev Ther Drug Carrier Syst 1993; 10: 1-28. (Pubitemid 23107931)
21. Cerritelli SM, Frolova EG, Feng C, et al. Failure to produce mitochondrial DNA results in emryonc lethality in RNase h1 null mice. Mol Cell 2003; 11: 807-815 (Pubitemid 36385132)
22. Dranitsyna SM, Kostenian IA, Astapova MV, et al. Nuclease activity of human interleukin 10. Bioorg Khim 2002; 28: 81-83
23. Merlino A, Ercole C, Picone D, et al. The buried diversity of bovine seminal ribonuclease: shape and cytotoxicity of the swapped non-covalent form of the enzyme. J Mol Biol 2008; 376: 427-437
24. Fucs SM, Rutkoski TJ, Kung VM, et al. Increasing the potency of a cytotoxin with an arginine graft. Protein Eng Des Sel 2007; 20: 505-509
25. Yuki S, Kondo Y, Kato F, et al. Noncytotoxic ribonuclease, RNase T1 induces tumor cell death via hemagglutinating virus of Japan envelope vector. Eur J Biochem 2004; 271: 3567-3572 (Pubitemid 39215346)
26. 2-terminal β-hairpin of the ribotoxin α-sarcin produces a nontoxic but active ribonuclease. J Biol Cem 2002; 277: 18632-18639
27. Ilinskaya O, Decker K, Koschinsky A, et al. Bacillus intermedius ribonuclease as inhibitor of cell proliferation and membrane current. Toxicology 2001; 156: 101-107
28. De Lorenzo C, Arciello A, Cozzolino R, et al. A fully hyman antitumor immuno-RNase selective for Erb B-2-positive carcinomas. Cancer Res 2004; 64: 4870-4874
29. De Lorenzo C, Troise F, Cafaro V, et al. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. Br J Cancer 2007; 97: 1354-1360 (Pubitemid 350114782)
30. Pouckova P, Zadinova M, Hlouskova D, et al. Polymerconjugated bovine pancreatic and seminal ribonucleases inhibit growth of human tumors in nude mice. J Control Release 2004; 95: 83-92. (Pubitemid 38167682)
31. Suzuki M, Saxena SK, Boix E, et al. Engeneering receptor-mediated cytotoxicity into human ribonucleases by steric blocade of inhibitor interaction. Nat Biotechnol 1999; 17: 227-228
32. Rutkoski TJ, Kurten EL, Mitchell JC, et al. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A. J Mol Biol 2005; 354: 41-51.
33. Soucek J, Pouckova P, Strohalm J, et al. Poly-[N-(2-hydroxypropyl) methacrylamide] conjugates of bovine pancreatic ribonuclease (RNase A) inhibit growth of human melanoma in nude mice. J Drug Target 2002; 10: 175-183 (Pubitemid 34467286)
34. Lehman K, Hause B, Altman D, et al. Tomato ribonuclease LX with the functional endoplasmic reticulum retention motif HDEF is expressed during programmed cell death processes, including xylem differentiation, germination and senescence. Plant Physiol 2001; 127: 436-449 (Pubitemid 32996747)
35. Siegmund D, Hadwiger P, Pfisenmaier K, et al. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL- induced apoptosis. Mol Med 2002; 8: 725-732 (Pubitemid 36337499)
36. Garcia MA, Guerra S, Jimenez V, et al. Anti-apoptotic and oncogenic properties of the ds-RNA-binding protein of vaccinia virus E3L. Oncogene 2002; 21: 8379-8387 (Pubitemid 36054880)
37. Grabarek J, Ardelt B, Du L, et al. Activation of caspases and serine proteases during apoptosis induced by onconase (Rainpirnase). Exp Cell Res 2002; 278: 61-71. (Pubitemid 34775446)
38. Lee JE, Shogen K. Mechanism of enhanced tumoricidal efficacy of multiforme small doses of rainpirnase, the novel cytotoxic ribonuclease, on lung cancer. Cancer Chemother Pharmacol 2008; 62: 337-346
39. Lee JE, Raines RT. Ribonucleases as novel chemotherapeutics: the rainpirnase example. Biodrugs 2008; 22: 53-58
40. Costanzi J, Sidransky D, Navon A, et al. Ribonucleases as a novel pro-apoptotic anticancer strategy: rewiev of the preclinical and clinical data for rainpirnase. Cancer Invest 2005; 23: 643-650 (Pubitemid 43286666)
41. Kim DH, Kim EG, Kalota A, et al. Possible mechanisms of improved radiation response by cytotoxic RNase, Onconase on A549 human cancer xenografts of nude mice. Adv Exp Med Biol 2007; 599: 53-59
42. Pavlakis N, Vogelzang NL. Ranpirnase - an antitumour ribonuclease: its potential role in malignant mesotelioma. Expert Opin Biol Ther 2006; 6: 391-399
43. Wiessen JL, Tomasi TB. DICER is regulated bycellular stresses and iterferons. Mol Immunol 2009; 46: 1222-1228
44. Baroni TE, Lastro MT, Ranganathan AC, et al. Ribonomic and short hairpin RNA gene silencing methods-to explore functional gene programs associated with tumor growth arrest. Methods Mol Biol 2007; 383: 227-244
45. Phylactou LA. Ribozyme and peptide-nucleic acid-based gene therapy. Adv Drug Deliv Rev 2000; 44: 97-108. (Pubitemid 30799161)
46. Bagheri S, Kashani-Sabet M. Ribozymes in the age of molecular therapeutics. Curr Mol Med 2004; 4: 489-506.
47. Fett JW, Strydom DJ, Lobb RR, et al. Isolation and characterization of angiogenic protein from human carcinoma cells. Biochemistry 1985; 24: 5480-5486 (Pubitemid 16228828)
48. Olson KA, Fett JW, French TC, et al. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA 1995; 92: 442-446
49. Olson KA, Byers HR, Key ME, et al. Prevention of human prostate metastases in athymic mice by antisense targeting of human angiogenin. Clin Cancer Res 2001; 7: 3598-3605
50. Piccoli R, Olson KA, Vallee BL, et al. Chimeric antiangiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc Natl Acad Sci USA 1998; 95: 4579-4583 (Pubitemid 28207955)
51. Li D, Bell J, Brown A, et al. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas and hepatocellular carcinomas. J Pathol 1994; 172: 171-175 (Pubitemid 24098668)
52. Etoh T, Shibuta K, Barnard GF, et al. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000; 6: 3545-3551 (Pubitemid 30694934)
53. Shimoyama S, Gansauge F, Gansauge S, et al. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996; 56: 2703-2706 (Pubitemid 26175721)
54. Eppenberger U, Kueng W, Shlaeppi JM, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16: 3129-3136 (Pubitemid 28417436)
55. Blaser J, Thomssen C, Schmitt M, et al. Angiogenin is a valuable prognostic factor in node-negative breast cancer. In: Schmitt M, Graeff H, Kindermann G, eds. Prospects in dia gnosis and treatment of breast cancer. Amsterdam: Excerpta Medica, 1994: 223-227
56. Olson KA, Byers HR, Key ME, et al. Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. Int J Cancer 2002; 98: 923-929
57. Hartmann A, Kunz M, Kostlin S, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999; 59: 1578-1583 (Pubitemid 29160129)
58. Eberle K, Oberbichler A, Trantakis C, et al. The expression of angiogenin in tissue samples of different brain tumors and cultured glioma cells. Anicancer Res 2000; 20: 1679-1684 (Pubitemid 30628185)
59. Shimoyama S, Kaminishi M. Increased angiogenin expression in gastric cancer correlated with cancer progression. J Cancer Res Clin Oncol 2000; 126: 468-474 (Pubitemid 30483161)
60. Barton DP, Cai A, Wendt K, et al. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997; 3: 1579-1586 (Pubitemid 27431566)
61. Hartmann A, Kunz M, Kostlin S, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999; 59: 1578-1583 (Pubitemid 29160129)
62. Ungurel S, Rappl G, Tilgen W, et al. Increased serum concentration of angiogenic factors in valignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-583 (Pubitemid 32112873)
63. Shapiro R, Vallee BL. Site-directed mutagenesis of histidine- 13 and histidine 114 of human angiogenin. Alanine derivates inhibit angiogenin-induced angiogenesis. Biochemistry 1989; 28: 7401-7408
64. Shapiro R, Fox EA, Riordan JF. Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. Biochemistry 1989; 28: 1726-1732 (Pubitemid 19072045)
65. Cyrran TP, Shapiro R, Riordan JF. Alteration of the enzymatic specificity of human angiogenin by site-directed mutagenesis. Biochemistry 1993; 32: 2307-2313 (Pubitemid 23094892)
66. Strydom DJ, Fett JW, Lobb RR, et al. Amino acid sequence of human tumor derived angiogenin. Biochemistry 1985; 24: 5486-5494
67. Kao RY, Jenkins JL, Olson KA, et al. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc Natl Acad Sci USA 2002; 99: 10066-10071
68. Jenkins JL, Shapiro R. Identification of small- molecule inhibitors of human angiogenin and characterization of their binding interactions guided by computational docking. Biochemistry 2003; 42: 6674-6687 (Pubitemid 36666108)
69. Polakowski IG, Lewis MK, Muthukkarrupan VR, et al. A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice. Am J Pathol 1993; 143: 507-517
70. Zheng ZH, Sun XJ, Fu WN, et al. Decresed expression of DICER1 in gastric cancer. Clin Med J (Engl) 2007; 120: 2099-2104 (Pubitemid 350268157)